SUBSCRIBE
SUBSCRIBE
News   Drug Development

OrthoLogic Corporation Announces Initiation of Dosing for AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring

February 29, 2008 | 
1 min read

TEMPE, Ariz., Feb. 29, 2008 (PRIME NEWSWIRE) -- OrthoLogic Corp. (NasdaqGM:OLGC - News) announced today the initiation of dosing for its AZX100 Phase 1 human clinical trial in dermal/hypertrophic scarring.

Clinical research Phase I
MORE ON THIS TOPIC
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
New York City, NY, USA - August 22, 2022: Pfizer world headquarters in New York City, USA. Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation.
Phase III
Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication
December 12, 2024
 · 
1 min read
 · 
Annalee Armstrong
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Cardiovascular disease
Keros Suspends Two Arms of Hypertension Study After Reports of Pericardial Effusion
December 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Prostate cancer
Candel Stock Skyrockets on Promising Phase III Prostate Cancer Data
December 12, 2024
 · 
3 min read
 · 
Tristan Manalac